Loading...
•
Sep 30, 2022
Fulcrum Therapeutics Q3 2022 Earnings Report
Fulcrum Therapeutics' financial results for Q3 2022 were reported, with a focus on clinical and operational execution
Key Takeaways
Fulcrum Therapeutics reported a net loss of $23.7 million for the third quarter of 2022, with collaboration revenue at $1.2 million and operating expenses totaling $25.5 million. The company's cash, cash equivalents, and marketable securities were $221.8 million as of September 30, 2022, expected to fund operations into late 2024.
Selected 12mg as the dose for the next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD).
Presented 96-week data from the Phase 2 ReDUX4 trial open label extension (OLE) study at the World Muscle Society (WMS) conference.
Completed equity raise of approximately $80.8 million in net proceeds, updating cash runway guidance into late 2024.
Announced the appointments of Chief Medical Officer and Chief Scientific Officer.
Forward Guidance
Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...